Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Maria Rinzivillo

Showing results (61-70 of 72) with videos related to

Pageof 8
Sort By:
Cancer Medicine|May 27, 2017
Prognostic impact of the cumulative dose and dose intensity of everolimus in patients with pancreatic neuroendocrine tumorsRossana Berardi, Mariangela Torniai, Sara Pusceddu, et al.
Carcinogenesis|January 9, 2018
Common genetic variants associated with pancreatic adenocarcinoma may also modify risk of pancreatic neuroendocrine neoplasmsOfure Obazee, Gabriele Capurso, Francesca Tavano, et al.
The Oncologist|August 14, 2014
Real-world study of everolimus in advanced progressive neuroendocrine tumorsFrancesco Panzuto, Maria Rinzivillo, Nicola Fazio, et al.
Endocrine|March 18, 2022
Prognostic significance of laterality in lung neuroendocrine tumorsAnna La Salvia, Irene Persano, Alessandra Siciliani, et al.
Scientific Reports|December 24, 2016
Common germline variants within the CDKN2A/2B region affect risk of pancreatic neuroendocrine tumorsDaniele Campa, Gabriele Capurso, Manuela Pastore, et al.
Journal of Neuroendocrinology|June 22, 2023
Proposal of early CT morphological criteria for response of liver metastases to systemic treatments in gastroenteropancreatic neuroendocrine tumors: Alternatives to RECISTLouis de Mestier, Matthieu Resche-Rigon, Clarisse Dromain, et al.
Endocrine|January 4, 2024
Epidemiology of gastroenteropancreatic neuroendocrine neoplasms: a review and protocol presentation for bridging tumor registry data with the Italian association for neuroendocrine tumors (Itanet) national databaseFrancesco Panzuto, Stefano Partelli, Davide Campana, et al.
Neuroendocrinology|October 10, 2018
Competitive Testing of the WHO 2010 versus the WHO 2017 Grading of Pancreatic Neuroendocrine Neoplasms: Data from a Large International Cohort StudyGuido Rindi, Catherine Klersy, Luca Albarello, et al.
Gastroenterology|April 16, 2018
Metformin Use Is Associated With Longer Progression-Free Survival of Patients With Diabetes and Pancreatic Neuroendocrine Tumors Receiving Everolimus and/or Somatostatin AnaloguesSara Pusceddu, Claudio Vernieri, Massimo Di Maio, et al.
JAMA Network Open|February 24, 2022
Association of Upfront Peptide Receptor Radionuclide Therapy With Progression-Free Survival Among Patients With Enteropancreatic Neuroendocrine TumorsSara Pusceddu, Natalie Prinzi, Salvatore Tafuto, et al.
Pageof 8

Showing results (61-70 of 72) with videos related to

Sort By:
Pageof 8
Cancer Medicine|May 27, 2017
Prognostic impact of the cumulative dose and dose intensity of everolimus in patients with pancreatic neuroendocrine tumorsRossana Berardi, Mariangela Torniai, Sara Pusceddu, et al.
Carcinogenesis|January 9, 2018
Common genetic variants associated with pancreatic adenocarcinoma may also modify risk of pancreatic neuroendocrine neoplasmsOfure Obazee, Gabriele Capurso, Francesca Tavano, et al.
The Oncologist|August 14, 2014
Real-world study of everolimus in advanced progressive neuroendocrine tumorsFrancesco Panzuto, Maria Rinzivillo, Nicola Fazio, et al.
Endocrine|March 18, 2022
Prognostic significance of laterality in lung neuroendocrine tumorsAnna La Salvia, Irene Persano, Alessandra Siciliani, et al.
Scientific Reports|December 24, 2016
Common germline variants within the CDKN2A/2B region affect risk of pancreatic neuroendocrine tumorsDaniele Campa, Gabriele Capurso, Manuela Pastore, et al.
Journal of Neuroendocrinology|June 22, 2023
Proposal of early CT morphological criteria for response of liver metastases to systemic treatments in gastroenteropancreatic neuroendocrine tumors: Alternatives to RECISTLouis de Mestier, Matthieu Resche-Rigon, Clarisse Dromain, et al.
Endocrine|January 4, 2024
Epidemiology of gastroenteropancreatic neuroendocrine neoplasms: a review and protocol presentation for bridging tumor registry data with the Italian association for neuroendocrine tumors (Itanet) national databaseFrancesco Panzuto, Stefano Partelli, Davide Campana, et al.
Neuroendocrinology|October 10, 2018
Competitive Testing of the WHO 2010 versus the WHO 2017 Grading of Pancreatic Neuroendocrine Neoplasms: Data from a Large International Cohort StudyGuido Rindi, Catherine Klersy, Luca Albarello, et al.
Gastroenterology|April 16, 2018
Metformin Use Is Associated With Longer Progression-Free Survival of Patients With Diabetes and Pancreatic Neuroendocrine Tumors Receiving Everolimus and/or Somatostatin AnaloguesSara Pusceddu, Claudio Vernieri, Massimo Di Maio, et al.
JAMA Network Open|February 24, 2022
Association of Upfront Peptide Receptor Radionuclide Therapy With Progression-Free Survival Among Patients With Enteropancreatic Neuroendocrine TumorsSara Pusceddu, Natalie Prinzi, Salvatore Tafuto, et al.
Pageof 8